Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug chemo combo shrink BRCA breast tumors before surgery?

NCT ID NCT07821229

Disease control Sponsor: N.N. Petrov National Medical Research Center of Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers test whether giving mitomycin plus carboplatin before surgery helps people with BRCA1 or BRCA2 mutations and locally advanced triple-negative breast cancer. The trial compares this combination, followed by paclitaxel, against standard chemotherapy. About 30 adults with newly diagnosed disease join, and doctors measure how much tumor remains in the breast and lymph nodes after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a chemotherapy combination of mitomycin and carboplatin
What this could lead to
If it works, this could give people with BRCA-linked triple-negative breast cancer a chemotherapy option that shrinks tumors more effectively before surgery.
What could go wrong
This is a small early study of 30 people, so results may not hold in larger groups. Chemotherapy can cause side effects, and the combination may not outperform standard treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed informed consent to participate in the study; 2. Histopathological confirmation of triple-negative breast cancer; 3. Stage: clinical T1-T4, N0-3, M0; 4. Positive molecular genetic test for BRCA1\|2 gene mutation (PCR test or NGS result); 5. Age \> 18 years; 6. ECOG status 0-1. Exclusion Criteria: 1. Prior administration of any systemic therapy for breast cancer; 2. Stage IV disease; 3. Severe uncontrolled chronic comorbidities or acute illnesses; 4. Renal dysfunction; 5. Age \> 70 years; 6. Presence of a second malignant tumor (except for previously cured malignancies); 7. Pregnancy or breastfeeding; 8. Negative molecular genetic test for BRCA1\|2 gene mutation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA 1 gene mutation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Fanconi anemia complementation group D1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA 1 gene mutation BRCA 2 gene mutation Breast cancer (early breast cancer)

Contacts and locations

Locations

  • N.N. Petrov National Medical Research Center of Oncology

    Saint Petersburg, 197758, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.